likely include discarding fact study showed benefit possibility results biased not convinced offer treatment patients basis tiny benefits clear effects risk expense inconvenience having treatment howard says fda gives aducanumab fast track approval likely monitor drug time confirm safe effective definitive data aducanumab findings plaque reducing approaches available years reiman says researchers studying types treatments including targeting infections inflammation successful therapy likely involve combination approach based multiple drugs according heather snyder vice president alzheimer association research advocacy group reiman says excited relationships aducanumab biological effects suggested clinical benefit additional work believes chance use biological tests find support accelerated approval effective